Environmental risk assessment of medicinal products for human use *Webinar*
€90,00

Started on 2021-12-09 90 min

Webinar Descrition

Environmental risk assessment of medicinal products for human use

In accordance with Article 8(3) of Directive 2001/83/EC, as amended, the evaluation of the potential environmental risks posed by the use of medicinal products shall be submitted, their environmental impact shall be assessed and, on a case-by-case basis, specific arrangements to limit this impact shall be considered.

An ERA is required for all new marketing authorisation applications for a medicinal product through a centralised, mutual recognition, decentralised or national procedure.
For type II variations, the ERA dossier should be updated if there is an anticipated increase in the environmental exposure, e.g. a new indication which results in an increase in the extent of the use.

For extension applications according to Annex II of Commission Regulation (EC) No 1085/2003, ERA is also required if there is an anticipated increase in the environmental exposure, e.g. an extension application of an oral medicinal product to include a dermal patch.

Agenda

Introduction

Environmental Risk Assessment requirements basics

ERA II

Q&A

Who should attend

Anyone with a responsibility for and/or interest in placing medicinal products on EU market.

Presenters

Dr. Martina Kubáňová, PhD., ERA expert

PaedDr. Martin Murin, REACH expert

Leave a comment